Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of ISIS 420915 in Familial Amyloid Polyneuropathy
2013-004561-13Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- May 2014
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inotersen in familial amyloid polyneuropathy (FAP), sponsored by Ionis Pharmaceuticals. Primary endpoint: Safety Endpoints. Started May 2014; status: completed.
02
Drugs
inotersen
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2013-004561-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004561-13.